欧林生物
(688319)
| 流通市值：112.30亿 | | | 总市值：112.30亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 361,322,181.04 | 157,803,808.92 | 704,160,325.32 | 506,920,470.94 |
| 营业总成本 | 310,823,899.43 | 136,476,818.31 | 659,117,720.56 | 440,264,661.39 |
| 其他经营收益 | | | | |
| 营业利润 | 57,093,154.54 | 32,392,401.95 | 30,857,171.48 | 55,605,554.73 |
| 利润总额 | 26,184,409.94 | 32,422,385.42 | 31,893,209.89 | 55,750,565.26 |
| 净利润 | -32,879,690.92 | 27,197,714.68 | 21,898,737.19 | 47,148,308.44 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | - | 27,197,714.68 | 21,898,737.19 | 47,148,308.44 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,075,290,027.48 | 998,755,242.25 | 996,333,512.94 | 964,223,718.56 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,024,425,704.49 | 1,021,156,465.74 | 1,026,736,270.08 | 980,745,921.32 |
| 资产总计 | 2,099,715,731.97 | 2,019,911,707.99 | 2,023,069,783.02 | 1,944,969,639.88 |
| 流动负债: | | | | |
| 流动负债合计 | 836,288,213.46 | 737,061,113.92 | 737,073,224.41 | 632,389,342.18 |
| 非流动负债: | | | | |
| 非流动负债合计 | 394,101,630.56 | 351,673,180.47 | 382,016,859.69 | 344,241,955.21 |
| 负债合计 | 1,230,389,844.02 | 1,088,734,294.39 | 1,119,090,084.1 | 976,631,297.39 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 869,325,887.95 | 930,868,035.65 | 903,678,718.78 | 959,846,714.83 |
| 股东权益合计 | 869,325,887.95 | 931,177,413.6 | 903,979,698.92 | 968,338,342.49 |
| 负债和股东权益合计 | 2,099,715,731.97 | 2,019,911,707.99 | 2,023,069,783.02 | 1,944,969,639.88 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 343,176,571.45 | 136,960,725.75 | 670,816,894.15 | 440,054,821.11 |
| 经营活动现金流出小计 | 413,577,497.93 | 162,385,314.26 | 565,323,116.79 | 407,009,586.17 |
| 经营活动产生的现金流量净额 | -70,400,926.48 | -25,424,588.51 | 105,493,777.36 | 33,045,234.94 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 135,125,136.99 | 135,125,136.99 | 200,525,572.57 | 95,287,167.1 |
| 投资活动现金流出小计 | 159,608,881.09 | 157,909,127.36 | 323,020,455.58 | 192,769,448.69 |
| 投资活动产生的现金流量净额 | -24,483,744.1 | -22,783,990.37 | -122,494,883.01 | -97,482,281.59 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 134,000,000 | 20,000,000 | 176,100,000 | 125,000,000 |
| 筹资活动现金流出小计 | 59,831,836.2 | 26,103,399.86 | 151,699,743.83 | 115,053,727.55 |
| 筹资活动产生的现金流量净额 | 74,168,163.8 | -6,103,399.86 | 24,400,256.17 | 9,946,272.45 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | - |
| 现金及现金等价物净增加额 | -20,716,506.78 | -54,311,978.74 | 7,399,150.52 | -54,490,774.2 |
| 期末现金及现金等价物余额 | 204,459,474.75 | 170,864,002.79 | 225,175,981.53 | 163,286,056.81 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -20,716,506.78 | - | 7,399,150.52 | - |
最新报告期：2026-09-07| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中信建投 | 汤然,刘若飞,贺菊颖 | -0.01 | 0.23 | 0.32 | 2026-09-07 |
| 中信建投 | 汤然,刘若飞,贺菊颖 | -0.12 | 0.16 | 0.25 | 2026-07-16 |